Sage Therapeutic Stock In The News

SAGE Stock  USD 5.47  0.08  1.44%   
Our overall analysis of Sage Therapeutic's news coverage and content from conventional and social sources shows investors' bearish mood towards Sage Therapeutic. The specific impact of Sage Therapeutic news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Sage Therapeutic's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Sage Therapeutic headlines in addition to utilizing other, more conventional financial analysis modules. Check out Sage Therapeutic Backtesting and Sage Therapeutic Hype Analysis.
For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.

Sage Therapeutic Today Top News and Investor Outlook

Yahoo News
After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
https://finance.yahoo.com/news/series-trial-setbacks-sage-therapeutics-141158013.html
 Neutral
Yahoo News
Sage Therapeutics, Inc. (SAGE): Worst 52-Week Low Stock to Buy Now
https://finance.yahoo.com/news/sage-therapeutics-inc-sage-worst-115449498.html
 Neutral
Yahoo News
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
https://finance.yahoo.com/news/biogen-terminates-collaboration-sage-therapeutics-143803708.html
 Neutral
Yahoo News
Sage Therapeutics, Inc. (SAGE) Hits 52-Week Lows After Trial Failures, According to Short Sellers
https://finance.yahoo.com/news/sage-therapeutics-inc-sage-hits-153413083.html
 Neutral
Yahoo News
Sage Therapeutics and Biogen Announce To...
https://finance.yahoo.com/news/sage-therapeutics-biogen-announce-topline-103000766.html
 Neutral
Yahoo News
15 Most Depressed States in the US
https://finance.yahoo.com/news/15-most-depressed-states-us-235721134.html
 Bearish
Yahoo News
12 Best All-Time Low Stocks To Invest In
https://finance.yahoo.com/news/12-best-time-low-stocks-232937492.html
 Bullish
Yahoo News
12 Best Depressed Stocks To Buy in 2024
https://finance.yahoo.com/news/12-best-depressed-stocks-buy-220907044.html
 Neutral
Yahoo News
25 Most Stressed Cities in the United States
https://finance.yahoo.com/news/25-most-stressed-cities-united-141632954.html
 Bearish
Yahoo News
Why Is Sage Therapeutics, Inc. (SAGE) Down 22% Since Last Earnings Report?
https://finance.yahoo.com/news/why-sage-therapeutics-inc-sage-153043398.html
 Neutral

Sage Therapeutic Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Sage and other traded companies coverage with news coverage. We help investors stay connected with Sage headlines for the 30th of November to make an informed investment decision based on correlating the impacts of news items on Sage Stock performance. Please note that trading solely based on the Sage Therapeutic hype is not for everyone as timely availability and quick action are needed to avoid losses.
Sage Therapeutic's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Sage Therapeutic investors visualize upcoming and past events in order to time the market based on Sage Therapeutic noise-free hype analysis.
Sage Therapeutic stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Sage earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Sage Therapeutic that are available to investors today. That information is available publicly through Sage media outlets and privately through word of mouth or via Sage internal channels. However, regardless of the origin, that massive amount of Sage data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Sage Therapeutic news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Sage Therapeutic relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Sage Therapeutic's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Sage Therapeutic alpha.

Sage Largest EPS Surprises

Earnings surprises can significantly impact Sage Therapeutic's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2014-11-11
2014-09-30-0.4-0.5-0.125 
2015-02-27
2014-12-31-0.43-0.57-0.1432 
2015-05-14
2015-03-31-0.49-0.66-0.1734 
2017-08-03
2017-06-30-1.67-1.88-0.2112 
2015-08-12
2015-06-30-0.68-0.9-0.2232 
2018-02-22
2017-12-31-1.99-1.750.2412 
View All Earnings Estimates

Sage Therapeutic Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Sage Therapeutic Stock. Current markets are slightly bearish. About 51% of major world exchanges and indexes are down. See today's market update for more information.
news
29th of November 2024
Sage Therapeutics Board Member, Dr. Jeffrey M. Jonas, Announces Retirement
at thelincolnianonline.com 
Investing News at Macroaxis
26th of November 2024
Sage Therapeutics announces board member retirement
at investing.com 
benzinga news
21st of November 2024
This Palo Alto Networks Analyst Turns Bullish Here Are Top 5 Upgrades For Thursday
at benzinga.com 
Yahoo News
20th of November 2024
After Failed Alzheimers Study, Sage Therapeutics Dalzanemdor Flunks Another Study In Patie...
at finance.yahoo.com 
Gurufocus Stories at Macroaxis
13th of November 2024
FMR LLC Adjusts Stake in Sage Therapeutics Inc
at gurufocus.com 
Gurufocus Stories at Macroaxis
5th of November 2024
Vanguard Group Incs Recent Transaction in Sage Therapeutics Inc
at gurufocus.com 
news
1st of November 2024
Wedbush Research Analysts Raise Earnings Estimates for SAGE
at thelincolnianonline.com 
bizjournals News
30th of October 2024
Sage to sunset first postpartum depression drug, focus on Zurzuvae
at bizjournals.com 
bizjournals News
24th of October 2024
Layoffs hit Raleigh pharma company amid shakeup
at bizjournals.com 
news
21st of October 2024
Shareholders of Sage Therapeutics, Inc. Should Contact Levi Korsinsky Before October 28, 2...
at accesswire.com 
news
16th of October 2024
Investors who lost money on Sage Therapeutics, Inc. should contact Levi Korsinsky about pe...
at accesswire.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sage Therapeutic in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sage Therapeutic's short interest history, or implied volatility extrapolated from Sage Therapeutic options trading.
When determining whether Sage Therapeutic is a strong investment it is important to analyze Sage Therapeutic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sage Therapeutic's future performance. For an informed investment choice regarding Sage Stock, refer to the following important reports:
Check out Sage Therapeutic Backtesting and Sage Therapeutic Hype Analysis.
For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.57)
Revenue Per Share
1.76
Quarterly Revenue Growth
3.371
Return On Assets
(0.30)
Return On Equity
(0.49)
The market value of Sage Therapeutic is measured differently than its book value, which is the value of Sage that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sage Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.